Point72 Asia (Singapore) Pte. Ltd. Castle Biosciences Inc Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $480 Billion
- Q2 2024
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Castle Biosciences Inc stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 253 shares of CSTL stock, worth $7,106. This represents 0.0% of its overall portfolio holdings.
Number of Shares
253Holding current value
$7,106% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CSTL
# of Institutions
171Shares Held
25.5MCall Options Held
511KPut Options Held
130K-
Black Rock Inc. New York, NY3.04MShares$85.5 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT2.33MShares$65.4 Million0.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.58MShares$44.3 Million0.0% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.5MShares$42.1 Million0.02% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.22MShares$34.2 Million0.44% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $739M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...